| Analysis | Incremental QALYs vs ST | Incremental costs vs ST | INMB at £20K(a) | Probability most CE option | Rank (95% CI) |
|---|---|---|---|---|---|
| ST | £0 | 0% | 3 (3, 5) | ||
| ICS | 0.000 | £104 | -£102 | 0% | 4 (3, 5) |
| PCS | 0.005 | -£2,815 | £2,908 | 28% | 2 (1, 2) |
| TXA | 0.190 | -£212 | £4,009 | 72% | 1 (1, 2) |
| ICS+TXA | 0.000 | £295 | -£303 | 0% | 5 (3, 5) |
Abbreviations: CE = cost-effective; CI = confidence intervals; ICS = intra-operative cell salvage; INMB = incremental net monetary benefit; PCS = post-operative cell salvage; QALYs = quality adjusted life years; ST = standard treatment; TXA = tranexamic acid.
INMB = NMB intervention A – NMB ST; Highest INMB = most cost-effective option at a £20,000 per QALY threshold; a negative INMB means that ST is more cost-effective than this option.
From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.